BMS and Prime ink potential $3.5bn deal to develop T cell therapies
As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime Medicine.
As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime Medicine.
What's Your Reaction?
